Universe Pharmaceuticals (UPC) Stock Price, News & Analysis

Company Overview

Universe Pharmaceuticals, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action. In parallel, Universe is exploring additional pipeline assets aimed at reducing post-operative scarring and controlling inflammation in anterior segment surgeries. Preclinical studies have demonstrated favorable pharmacokinetics and tissue penetration in animal models, supporting the potential for once-daily dosing regimens.

Headquartered in the United Kingdom with a research subsidiary in the United States, Universe Pharmaceuticals maintains collaborations with academic institutions and contract development organizations to accelerate its drug development programs. The company is led by a management team with extensive experience in ophthalmology drug development and regulatory strategy, positioning it to advance its candidates through late-stage clinical trials and toward commercialization.

Key Stats

• Today's Range: $3.97 to $4.17
• 50-Day Range: $3.27 to $4.40
• 52-Week Range: $2.51 to $756.00
• Volume: 11,045 shs
• Average Volume: 94,326 shs
• Market Capitalization: $2.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Universe Pharmaceuticals Stock Analysis - MarketRank™

Universe Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Universe Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Universe Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.25% of the float of Universe Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Universe Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Universe Pharmaceuticals has recently decreased by 27.45%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Universe Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Universe Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.25% of the float of Universe Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Universe Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Universe Pharmaceuticals has recently decreased by 27.45%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.33

News Sentiment

Universe Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Universe Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Universe Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

57.38% of the stock of Universe Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.18% of the stock of Universe Pharmaceuticals is held by institutions.

UPC Stock Analysis - Frequently Asked Questions

How have UPC shares performed this year?

Universe Pharmaceuticals' stock was trading at $4.67 at the beginning of the year. Since then, UPC shares have decreased by 14.1% and is now trading at $4.01.

When did Universe Pharmaceuticals IPO?

Universe Pharmaceuticals (UPC) raised $30 million in an IPO on Tuesday, March 23rd 2021. The company issued 5,000,000 shares at $5.00-$7.00 per share. Univest Securities, LLC served as the underwriter for the IPO.

How do I buy shares of Universe Pharmaceuticals?

Shares of UPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/14/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPC
• CIK: 1809616
• Web: N/A
• Phone: 86-0796-8403309
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 2.78
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $19.29 million
• Price / Sales: 0.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7,528.62 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 563,000
• Free Float: 240,000
• Market Cap: $2.26 million
• Optionable: N/A
• Beta: 1.44